# DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymp

Source: https://onco.cc/trials/nct04920617/  
OnCo record `nct04920617` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab, Cyclophosphamide in diffuse large b-cell lymphoma, run by ImmunoVaccine Technologies, Inc. (IMV Inc.), now recruiting.

## Summary

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma is a phase 2 interventional study registered as NCT04920617 by ImmunoVaccine Technologies, Inc. (IMV Inc.), with 102 participants planned, started 2021-06-18 and due to reach its primary completion in 2024-10. Interventions recorded: DPX-Survivac, Pembrolizumab, CPA. Conditions listed: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04920617
- Phase: 2
- Setting: A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
- Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Enrolled: 102

## Sources

- ClinicalTrials.gov NCT04920617: https://clinicaltrials.gov/study/NCT04920617

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct04920617.json